Citadel Advisors
RDY icon

Citadel Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Citadel Advisors’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-800
Closed -$10.6K – 14640
2025
Q1 		$10.6K Sell
800
-10,800
-93% -$149K ﹤0.01% 13534
2024
Q4 		$183K Sell
11,600
-18,900
-62% -$284K ﹤0.01% 10591
2024
Q3 		$485K Buy
30,500
+16,500
+118% +$266K ﹤0.01% 8327
2024
Q2 		$213K Buy
14,000
+2,000
+17% +$28.7K ﹤0.01% 9787
2024
Q1 		$176K Buy
12,000
+9,500
+380% +$139K ﹤0.01% 10532
2023
Q4 		$34.8K Sell
2,500
-2,500
-50% -$33.4K ﹤0.01% 12136
2023
Q3 		$66.9K Buy
5,000
+4,000
+400% +$54.1K ﹤0.01% 11384
2023
Q2 		$12.6K Sell
1,000
-5,000
-83% -$58.4K ﹤0.01% 13070
2023
Q1 		$68.3K Buy
6,000
+5,500
+1,100% +$59.4K ﹤0.01% 11774
2022
Q4 		$5.17K Buy
+500
New +$5.39K ﹤0.01% 14028
2022
Q1 		– Sell
-28,000
Closed -$366K – 14410
2021
Q4 		$366K Sell
28,000
-41,000
-59% -$517K ﹤0.01% 10464
2021
Q3 		$899K Buy
69,000
+52,500
+318% +$700K ﹤0.01% 8427
2021
Q2 		$243K Sell
16,500
-33,500
-67% -$468K ﹤0.01% 11756
2021
Q1 		$614K Sell
50,000
-7,500
-13% -$96.3K ﹤0.01% 9239
2020
Q4 		$820K Buy
57,500
+22,500
+64% +$303K ﹤0.01% 7207
2020
Q3 		$487K Buy
35,000
+14,000
+67% +$167K ﹤0.01% 7347
2020
Q2 		$223K Buy
+21,000
New +$214K ﹤0.01% 8368
2018
Q3 		– Sell
-35,000
Closed -$225K – 9606
2018
Q2 		$225K Sell
35,000
-34,000
-49% -$214K ﹤0.01% 7686
2018
Q1 		$451K Sell
69,000
-44,500
-39% -$312K ﹤0.01% 6064
2017
Q4 		$853K Sell
113,500
-28,000
-20% -$202K ﹤0.01% 4885
2017
Q3 		$1.01M Buy
+141,500
New +$1.02M ﹤0.01% 4312

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citadel Advisors's RDY Position: Q1 2026 in Review

Citadel Advisors increased its Dr. Reddy's Laboratories (RDY) stake by 38% in Q1 2026, buying an estimated $1.7M and bringing the position to 446,606 shares worth $6.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3996.

Citadel Advisors first reported a position in RDY in Q4 2013 and has held it in 30 quarters since. The position peaked at $18.7M in Q2 2023. 248 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Citadel Advisors held 446,606 shares of Dr. Reddy's Laboratories worth $6.19M as of Q1 2026.
  • Citadel Advisors bought 122,157 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $1.7M.
  • Dr. Reddy's Laboratories made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3996 holding.
  • Citadel Advisors first reported a position in Dr. Reddy's Laboratories in Q4 2013 and has held it in 30 quarters since.
  • Citadel Advisors's Dr. Reddy's Laboratories position peaked at $18.7M in Q2 2023.
  • 248 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.